Alexander Spira
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 132
- Cancer Immunotherapy and Biomarkers 38
- Lung Cancer Research Studies 33
- Colorectal Cancer Treatments and Studies 33
- HER2/EGFR in Cancer Research 19
-
- Lung Cancer Treatments and Mutations 113
- Gastric Cancer Management and Outcomes 14
- Lung Cancer Diagnosis and Treatment 14
- Co-authors
- David S. Ettinger (3 shared papers)Preston A. Marx (3 shared papers)D D Ho (2 shared papers)Richard A. Koup (2 shared papers)Steven M. Wolinsky (2 shared papers)Bruce Kendrick Patterson (2 shared papers)J. Matthew Mahoney (2 shared papers)Karen Velastegui (8 shared papers)
- Journals
- Annals of Oncology (76 papers)Journal of Thoracic Oncology (30 papers)Journal of Clinical Oncology (27 papers)Clinical Cancer Research (13 papers)European Journal of Cancer (9 papers)
- Partner nations
- United StatesSpainUnited Kingdom
In The Last Decade
Alexander Spira
277 papers receiving 19.9k citations
Alexander Spira's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 9.6k
- Pulmonary and Respiratory Medicine 8.0k
- Virology 730
- Cancer Research 2.1k
- Immunology 2.2k
Countries citing papers authored by Alexander Spira
This map shows the geographic impact of Alexander Spira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Spira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Spira more than expected).
Fields of papers citing papers by Alexander Spira
This network shows the impact of papers produced by Alexander Spira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Spira. The network helps show where Alexander Spira may publish in the future.
Co-authors
The 25 scholars most cited alongside Alexander Spira, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 289 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Hit paper breakdown → | 2018 | 2972 |
| 2 | Sotorasib for Lung Cancers with KRAS p.G12C Mutation Hit paper breakdown → | 2021 | 1325 |
| 3 | Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 773 |
| 4 | Multidisciplinary Management of Lung Cancer Hit paper breakdown → | 2004 | 761 |
| 5 | Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation Hit paper breakdown → | 2022 | 727 |
| 6 | First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations Hit paper breakdown → | 2008 | 726 |
| 7 | Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial Hit paper breakdown → | 2015 | 678 |
| 8 | Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. Hit paper breakdown → | 1996 | 601 |
| 9 | Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study Hit paper breakdown → | 2021 | 507 |
| 10 | Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study Hit paper breakdown → | 2015 | 505 |
| 11 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2013 | 452 |
| 12 | Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 431 |
| 13 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Hit paper breakdown → | 2017 | 414 |
| 14 | 1996 | 403 | |
| 15 | Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial Hit paper breakdown → | 2012 | 378 |
| 16 | Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C Hit paper breakdown → | 2022 | 369 |
| 17 | Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial Hit paper breakdown → | 2022 | 327 |
| 18 | Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial Hit paper breakdown → | 2021 | 271 |
| 19 | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial Hit paper breakdown → | 2020 | 261 |
| 20 | Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC Hit paper breakdown → | 2024 | 250 |
About Alexander Spira
Alexander Spira is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology, having authored 289 papers that have together received 20.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (113 papers), Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Research Studies (33 papers), Colorectal Cancer Treatments and Studies (33 papers), HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (18 papers), Gastric Cancer Management and Outcomes (14 papers) and Lung Cancer Diagnosis and Treatment (14 papers). The work is most often cited by research in Oncology (9.6k citations), Pulmonary and Respiratory Medicine (8.0k citations), Virology (730 citations), Cancer Research (2.1k citations) and Immunology (2.2k citations). Alexander Spira has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include David S. Ettinger, Preston A. Marx, D D Ho, Richard A. Koup, Steven M. Wolinsky, Bruce Kendrick Patterson, J. Matthew Mahoney, Karen Velastegui, Sai‐Hong Ignatius Ou and Minal A. Barve. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Journal of Clinical Oncology, Clinical Cancer Research and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.